The primary data collection for the Phase 3 trial (NCT05073835) investigating semaglutide 3.0 mg/ml in patients with poor weight loss following bariatric surgery was completed on March 31, 2025. This milestone indicates that the main data for the study, which aims to evaluate the drug's efficacy in improving weight loss and metabolic outcomes, has been gathered.
Background
Semaglutide, marketed under various brand names, is a glucagon-like peptide-1 (GLP-1) receptor agonist. This particular trial, titled "Semaglutide 2.4 mg in Patients With Poor Weight-loss," focuses on a specific and challenging patient population: individuals who have undergone bariatric surgery (gastric bypass or sleeve gastrectomy) but have experienced poor weight loss outcomes. The study addresses conditions such as obesity, diabetes, and metabolic syndrome within this context.
Trial design
The trial, identified as NCT05073835, is a Phase 3, double-blinded, randomised, placebo-controlled study. It enrolled 70 participants who had previously undergone bariatric surgery and were experiencing poor weight loss. Participants were assigned to receive either semaglutide 3.0 mg/ml via subcutaneous administration for 68 weeks or a placebo. The primary aim of this trial is to determine the extent to which semaglutide causes greater percentage weight loss (%WL), reduction in adiposity, improvement in metabolic and inflammatory indices, and health-related quality of life (HRQoL) compared to placebo in this specific patient group.
What this means
The primary completion of this Phase 3 trial signifies that all planned primary data points have been collected. This is a critical step towards understanding the potential role of semaglutide as an intervention for patients struggling with insufficient weight loss after bariatric surgery. The findings are anticipated to provide valuable evidence for clinicians and patients seeking additional therapeutic options for managing obesity and related metabolic conditions in this specific population. Once analyzed, the results will shed light on whether semaglutide can offer a meaningful improvement in weight management and overall health outcomes for these individuals.
Source
The information regarding the primary completion of this clinical trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05073835, titled "Semaglutide 2.4 mg in Patients With Poor Weight-loss," was posted on March 31, 2025 on clinicaltrials.gov.